Early Data on Amgen ’s Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types

< p > Amgen today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors -- bevacizumab or motesanib diphosphate (AMG 706) -- compared with either treatment alone (p < 0.05). < /p > < p > 04/13/2008 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news